Apellis Pharmaceuticals Inc

Infinity Pharmaceuticals is an innovative cancer drug discovery and development company that specializes in small molecule drug technologies to bring new medicines to patients. The company s most-advanced drug candidate, IPI-504, is a proprietary, targeted cancer therapy that preferentially induces the death of cancer cells through the inhibition of the heat shock protein 90 complex. In preclinical animal studies of a wide variety of hematological malignancies and solid tumors, IPI-504 has demonstrated utility as both a single agent and in combination with other therapies. Infinity Pharmaceuticals owns all rights to the IPI-504 and commenced Phase I clinical trials in July 2005. The company also has an advanced drug candidate in IPI-609, another proprietary small molecule that operates through inhibition of the Hedgehog cell signaling pathway. Infinity also owns all rights to IPI-609. Since Infinity was founded in 2001, the company has raised more than $130 million from corporate partnerships and premier venture capitalists.

AVEO Pharmaceuticals Inc. is an oncology-focused biopharmaceutical company based in Cambridge, MA, dedicated to developing innovative medicines aimed at improving the lives of cancer patients. The company is committed to pursuing advanced solutions in cancer treatment through its research and development efforts. As part of its mission, AVEO emphasizes a culture of collaboration and innovation, working closely with partners and scientific advisors to enhance its therapeutic offerings. The company is driven by a passion for delivering better outcomes for patients facing the challenges of cancer. Generated from the website

Takeda Pharmaceuticals USA, based in Cambridge, MA, is a global pharmaceutical company dedicated to creating better health for people and a brighter future for the world. With a focus on research and development, Takeda strives to transform lives through innovative medicines in areas such as gastrointestinal and inflammation, rare diseases, oncology, neuroscience, plasma-derived therapies, and vaccines. Committed to sustainability and corporate responsibility, Takeda emphasizes access to medicines, ethical practices, and transparency in governance. Through collaboration with diverse colleagues and a patient-centered approach, Takeda continues to advance science and technology to improve healthcare outcomes worldwide. Generated from the website